RE:Price Target I am not sure these were there in the last IP.
Page 21:
"Key Differentiators Underpinning Regulatory and Commercial Viability
First-in-class MOA with an upstream approach to underlying causes of NASH De-risked, late-stage clinical program with demonstrated proof-of-concept Statistically significant results in a harder-to-treat patient population, driving optimism for efficacy in a broader, non-HIV patient population 10+ year product history contributing to an extensively documented safety and tolerability profile"
Page 22:
"Large, Underserved Population Significant Risk Factors and Comorbidities 22 BMI Waist circumference Lipodystrophy (Visceral Adipose Tissue – VAT) Diabetes / Glucose Hypertension Cholesterol CD4 count HCV co-infection Alanine / Aspartate Aminotransferase 1 2 3 4 5 6 Sources: GlobalData 2017, Pharma Point Human Immunodeficiency Virus HIV Global Drug Forecast and Market Analysis to 2025.; Wall Street consensus forecast figures based on Intercept and Madrigal, and company estimates 230 537 84 607 NASH HIV F2 / F3 NASH HIV 37% 2019 U.S. NASH HIV Prevalence"
scarlet1967 wrote: " Theratechnologies : National Bank of Canada resumes coverage with C$3.75 PT"
Also investors presentation is up.